Research Antibodies Market Size, Share & Trends Report

Research Antibodies Market Size, Share & Trends Analysis Report By Product (Primary, Secondary), By Type (Monoclonal Antibodies, Polyclonal Antibodies), By Technology, By Source, By Application, By End-use, By Region, And Segment Forecasts, 2021 - 2028

  • Published Date: Jul, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-2-68038-124-5
  • Format: Electronic (PDF)
  • Historical Data: 2018 - 2019
  • Number of Pages: 140

Report Overview

The global research antibodies market size was estimated at USD 3.6 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.4% from 2021 to 2028. Antibodies are proteins made by B cells and are a part of the human body’s immune system. These molecules can bind themselves to specific molecules that make them an ideal probe for cell research purposes. They are also used to isolate and aid in the identification of molecules of interest in cells. Currently, antibodies are one of the most important tools to study the function of a protein in cells. Increasing incidence of neurodegenerative diseases such as Huntington’s disease, Multiple Sclerosis, and Parkinson’s diseases is further encouraging research activities in neurobiology. A rise in the geriatric population and lack of available treatments has also led to a substantial rise in the demand for research antibodies to develop personalized medicines, advanced therapeutics, and novel and effective treatments.

U.S. research antibodies market size, by product, 2018 - 2028 (USD Billion)

The outbreak of COVID-19 has created lucrative opportunities in the market. Several pharmaceutical giants are conducting extensive R&D activities to develop novel vaccines, treatment approaches, and testing kits for this pandemic. These rigorous R&D activities for the development of novel vaccine and treatment approaches have significantly increased demand for research antibodies. Furthermore, several private and government organizations are taking drastic initiatives to support the development of COVID-19 vaccines and therapeutics. In 2020, GlaxoSmithKline invested USD 250 million in Vir Biotechnologies, a San Francisco-based clinical-stage immunology company, to support its antibody-drug development program for COVID-19. Similarly, in April 2020, the federal government granted USD 14.5 million to Emergent BioSolutions-a Maryland-based biopharmaceutical company-to work on an antibody-drug trial for COVID-19. However, this pandemic has slowed down the discovery and development activities of biological products for other applications, such as oncology and rare diseases, which may hamper growth up to some extent.

A considerable rise in the number of R&D activities by various biopharmaceutical and pharmaceutical companies to develop innovative products is predominantly driving the market. For instance, in January 2018, Abcam Plc. signed a definitive license agreement with Roche in order to obtain the exclusive rights to Spring Bioscience Corporation’s product portfolio only for research purposes. The product portfolio consists of 243 recombinant rabbit monoclonal antibodies that have been optimized for immunohistochemistry. Similarly, in February 2019, Immunoprecise Antibodies Ltd. in collaboration with the Foundation for Innovative New Diagnostics (FIND) announced the results for their research collaboration project. This project involved the development of rabbit monoclonal antibodies along with the Bcell select platform that helps in recognizing the TB biomarker.

Furthermore, the availability of technologically advanced diagnostic and therapeutic products using research antibodies is anticipated to fuel market growth in the near future. For instance, in October 2019, Y-Biologics and Pascal Biosciences Inc. signed a collaborative research agreement aimed towards facilitating the discovery and development of various novel bio-specific antibodies. As per the agreement, Y-Biologics will be contributing ALiCE, its novel antibody platform technology, and Pascal Biosciences Inc. will be utilizing the company’s antibody products.

Increasing funds provided by government bodies for proteomics and genomics research is another factor anticipated to boost market growth during the forecast period. Genomic technologies are being utilized to identify genetic factors involved in the leading causes of death globally. In 2018, NIH funded various genome research centers to accelerate and advance precision medicine discoveries. The ‘All of Us’ research program which is a part of NIH was awarded USD 28.6 million to establish three genome centers around the country. However, factors such as high costs and stringent government regulations are expected to restrain the market growth during the forecast period.

Product Insights

The primary antibodies segment held a dominant share of 66.1% in 2020 owing to high adoption due to benefits such as easy availability, greater specificity, and suitability to various research needs. Additionally, an increase in the development of primary antibodies using rabbit, goat, mouse and other species as hosts, which are supplied in a wide range to suit research needs is further accelerating the segment growth. They are also used for measurement, detection, as well as purification of biomolecules or proteins in various applications such as flow cytometry, ELISA, immunochemistry or western blotting.

The secondary antibodies segment is anticipated to grow at a steady rate as they are more convenient and economical to develop. The availability of ready-to-use forms is further expected to raise the demand for secondary research antibodies. These products aid in the detection, sorting, and purification of the targeted antigens, thereby enhancing the efficiency of the product development activities. Thermo Fisher Scientific Inc. offers fluorescent dye conjugated secondary antibodies that facilitate the identification of proteins in a wide range of applications such as western blotting, fluorescent cell imaging, and immunohistochemistry, among others.

Type Insights

The monoclonal segment dominated the market and accounted for the largest revenue share of 64.7% in 2020 owing to a significant rise in the number of research activities in genomics that require technologically advanced genetic platforms. These products are used in the discovery and development of new therapies to treat diseases such as cancer, as they work either by attaching or blocking antigens on cancer cells.

The polyclonal antibodies segment is anticipated to grow at a steady rate during the forecast period. These antibody structures are critical in histopathological tissue analysis and antigen purification. Moreover, growing awareness among individuals regarding treatment of cancer and other chronic diseases has led to increased demand for advanced treatment and diagnosis options globally. Polyclonal antibodies offer advantages such as stability, favorable storage techniques, great affinity, and high suitability towards technologies such as ELISA and western blotting. Agilent provides multipurpose antibody-based products that consist of concentrated polyclonal antibodies used majorly for techniques other than immunochemistry. For instance, C1q Complement/FITC is a polyclonal rabbit anti-human antibody that is intended for immuno-fluorescent demonstration of C1q complement in human tissues.

Technology Insights

The western blotting segment dominated the market and accounted for the largest revenue share of 54.0% in 2020 due to the increasing prevalence of diseases that have limited treatment options. Western blotting is mostly being preferred over other technologies such as ELISA tests and flow cytometry among others for the detection of HIV antibodies due to greater accuracy provided by western blotting technique.

The immunohistochemistry segment accounted for the second-largest revenue share in 2020. The segment is expected to grow at a steady rate owing to its major use in cancer diagnosis and prognosis of tumors. Other applications of immunohistochemistry include identification of enzymes, antigens, tumor suppressor genes, and tumor cell proliferation. Moreover, growing awareness levels amongst patients and healthcare professionals and rise in healthcare expenditure are some of the factors facilitating the growth of flow cytometry segment. In addition, advantages offered by cell-based assays such as high sensitivity and productivity, and ease of use are some of the factors expected to drive the growth of this segment.

Source Insights

In 2020, the mouse segment dominated the market and held the largest revenue share of 50.3%, as they are easier to produce and are more specific in nature. The structural similarities in mice and human antibodies are the prime reason for their high adoption rate. Upgradation in the development process of mouse-based research antibodies such as the adoption of hybridoma technology that helps in the production of monoclonal antibodies in various specialized cells is expected to boost market growth.

The rabbit segment is anticipated to witness considerable growth over the forecast period. The antibodies that are produced by rabbits usually have about 10 to 100 fold greater affinity than those produced by mice. Moreover, the rabbit immune system is adept in the generation of antibodies that are capable of distinguishing similar molecules that have a subtle variation in their structures. Goat antibodies are also anticipated to witness constant growth during the forecast period. This can be attributed to the preference for goats as an animal source when it comes to large-scale production. Besides, the use of goat antibodies proving to be a more cost-effective option for most large-scale research projects.

Application Insights

The oncology segment dominated the market and accounted for the largest revenue share of 37.1% in 2020, owing to the rise in the prevalence of cancer in key geographies. According to the International Agency for Research on Cancer, the global cancer incidence was estimated to be 18.1 million in 2018. Additionally, 9.6 million cancer deaths were also recorded in the same year. The study also mentioned that 1 in 6 women and 1 in 5 men are estimated to develop cancer during their life span. The same source also estimated the 5-year prevalence of cancer to reach 43.8 million. Therefore, the growing prevalence of cancer across the globe is expected to increase the usage of research antibodies to develop various diagnoses and treatment options.

Key market players such as Merck Millipore offer various antibodies from their product portfolio to enhance the study of different stages of cancer such as autophagy, angiogenesis, apoptosis, and metastasis. Antibodies that are adopted in cancer research, as well as diagnosis, facilitate the generation of reliable output data from genomic, proteomic, and epigenomic studies that are very crucial for studies related to disease progression.

The stem cells segment is anticipated to show lucrative growth over the forecast period, owing to increasing government investment, which has been key in encouraging researchers to continue to stem cell-based R&D for various therapeutic applications. For instance, in March 2019, the Australian Federal Government invested $150 million in Stem Cells Australia and the University of Melbourne to support R&D intended for stem cell research and to explore novel methods to treat various life-threatening conditions such as stroke, congenital heart, and kidney disease. Similarly, scientists at Burnet Institute led a study that identified human antibodies that can prevent the malaria parasite from entering blood cells. The study focused on RH5 protein, produced by a malarial parasite that binds to proteins on RBCs, causing serious infection within the immune system.

End-use Insights

The pharmaceutical and biotechnology companies segment constituted a dominant share of 60.6% in 2020, due to the rise in the use of assays for the diagnosis of various diseases and the growing prevalence of cancer and chronic diseases such as diabetes. Besides, the academic and research institutes segment also accounted for a considerable share due to the presence of academic groups that conduct various studies and researches related to antibodies. Benefits such as a greater understanding of the biological process and complex systems are anticipated to exhibit exponential growth opportunities.

Global research antibodies market share, by end-use, 2020, (%)

The contract research organizations segment is anticipated to witness a significant CAGR during the forecast period. This growth is attributed to various benefits that are offered by these organizations such as higher efficiency of services, enhanced productivity, cost advantages, and high focus on the core areas of development. Also, according to a survey published in NCBI, outsourcing results in up to 60% cost savings and ensures high quality. In addition, contract services eliminate the need for infrastructure, therefore contributing to the significant cost reduction factor associated with it.

Regional Insights

North America dominated the research antibodies market in 2020 by capturing the largest revenue share of 35.1%. Increasing focus on biomedical, stem cells, and cancer research is a key factor contributing towards its high market share. The rising prevalence of chronic diseases such as cardiovascular and blood diseases is expected to fuel market growth. In the year 2018, the American Cancer Society, Inc. estimated about 1,735,350 new cases of cancer in the U.S. with over 609,640 cancer deaths. Thus, there is an increasing focus on cancer research and stem cell research activities. Stem cell therapy is the most promising technique to treat severe medical conditions including cancer and blood diseases. Therefore, a rising number of biotechnology and biopharmaceutical companies are adopting advanced research antibodies products for stem cells research, which is projected to drive the market in the region.

The rise in R&D activities undertaken by academic institutions is anticipated to boost the market in the Asia Pacific region. For instance, in June 2019, researchers at the Tsinghua University collaborated with the China Medical University and the Vaccine Research Center at the NIH to initiate research on the identification as well characterization of HIV-1 strains along with potent and broad resistance against a wide number of neutralizing antibodies. This research was encouraged by the National Natural Science Foundation Award, Ministry of Science and Technology of China, and Gates Foundation Grand Challenges China. Thus, a large number of R&D activities for the discovery of novel therapeutic and diagnostic applications of antibodies funded by the government bodies are the factors expected to fuel market growth.

Key Companies & Market Share Insights

Strategic initiatives are undertaken by major market players such as collaborations, mergers and acquisitions, for various R&D activities, and product launches among others are expected to boost the market growth during the forecast period. For instance, in 2018, Thermo Fisher Scientific Inc., collaborated with Montreal Neurological Institute with an aim to develop improved and new methods to both characterize and produce antibodies for advanced neurological research associated with Amyotrophic lateral sclerosis, Parkinson's disease, and other brain diseases. Similarly, in September 2018, Roche announced the acquisition of Tusk Therapeutic Ltd. Tusk is a developer of an antibody that has a novel mode of action aimed at depleting regulatory T cells. Some of the prominent players in the research antibodies market include:

  • Abcam Plc

  • Bio-rad Laboratories

  • Becton Dickinson & Company

  • Merck Millipore

  • Lonza Group

  • Thermo Fisher Scientific, Inc.

  • Cell Signalling Technology, Inc.

  • F. Hoffmann La Roche Ltd.

  • Agilent Technologies

  • Perkinelmer, Inc.

Research Antibodies Market Report Scope

Report Attribute

Details

Market size value in 2021

USD 3.8 billion

Revenue forecast in 2028

USD 5.9 billion

Growth Rate

CAGR of 6.4% from 2021 to 2028

Base year for estimation

2020

Historical data

2018 – 2019

Forecast period

2021 – 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, type, technology, source, application, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; Spain; France; Italy; Russia; China; India; Japan; Australia; Singapore; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE

Key companies profiled

Abcam Plc; Bio-rad Laboratories; Becton Dickinson & Company; Merck Millipore; Lonza Group; Thermo Fisher Scientific, Inc.; Cell Signalling Technology, Inc.; F. Hoffmann La Roche Ltd.; Agilent Technologies; Perkinelmer, Inc.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2028. For the purpose of this study, Grand View Research has segmented the global research antibodies market report on the basis of product, type, technology, source, application, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2018 - 2028)

    • Primary

    • Secondary

  • Type Outlook (Revenue, USD Million, 2018 - 2028)

    • Monoclonal Antibodies

    • Polyclonal Antibodies

  • Technology Outlook (Revenue, USD Million, 2018 - 2028)

    • Immunohistochemistry

    • Immunofluorescence

    • Western Blotting

    • Flow Cytometry

    • Immunoprecipitation

    • ELISA

    • Other Technologies

  • Source Outlook (Revenue, USD Million, 2018 - 2028)

    • Mouse

    • Rabbit

    • Goat

    • Other Sources

  • Application Outlook (Revenue, USD Million, 2018 - 2028)

    • Infectious Diseases

    • Immunology

    • Oncology

    • Stem Cells

    • Neurobiology

    • Other Applications

  • End-use Outlook (Revenue, USD Million, 2018 - 2028)

    • Academic & Research Institutes

    • Contract Research Organizations

    • Pharmaceutical & Biotechnology Companies

  •  Regional Outlook (Revenue, USD Million, 2018 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • Spain

      • France

      • Italy

      • Russia

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Australia

      • Singapore

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.